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The presenilin-containing γ-secretase complex is an unusual membrane-embedded 
protease that processes a wide variety of integral membrane proteins, clearing protein 
stubs from the lipid bilayer and participating in critical signaling pathways. The protease 
is also central to Alzheimer’s disease and certain cancers and is therefore an important 
therapeutic target. Here we highlight recent progress in deciphering the role of presenilin/γ-
secretase in biology and medicine and pose key questions for future study.The importance of the presenilin/ 
γ-secretase complex has vastly 
surpassed its initial identity as the 
enzyme that generates the amyloid-β 
protein, an aberrant form of which 
is implicated in Alzheimer’s disease 
(AD). This conserved and omnipres-
ent membrane protein complex is 
required for life in all multicellular ani-
mals. Its roster of client substrates is 
large and growing and includes some 
of the most interesting and widely 
studied protein families in biology. 
Despite intense study for more than 
a decade, much still needs to be 
learned about presenilin in health and 
disease.
The discovery of presenilins as 
ubiquitous intramembrane pro-
teases in metazoans exemplifies an 
emerging trend in biology. The tra-
ditional distinction between basic 
and applied research is becoming 
increasingly blurred, as studies initi-
ated with a strictly disease-oriented 
focus uncover fundamental biological 
mechanisms. In the example of pre-
senilin, the quest for genetic causes 
of AD led to linkage analysis and posi-
tional cloning that identified a new 
human gene (originally called S182) 
(Sherrington et al., 1995), mutations in 
which produce the most severe form 
of dominantly inherited AD. Although 
the function of this polytopic mem-
brane protein could not be predicted 
from its primary structure, it was soon 
shown to be the first intramembrane 
aspartyl protease (Wolfe et al., 1999). This knowledge emerged around the 
time that site 2 protease (S2P) was 
identified as a metalloprotease that 
cleaves sterol regulatory element 
binding protein within the Golgi mem-
brane as part of cholesterol homeo-
stasis (Brown et al., 2000). These 
discoveries established the existence 
of intramembrane cleaving proteases 
(I-CLiPs) (reviewed in Wolfe and 
Kopan, 2004) and led to the recogni-
tion of a hitherto unknown signaling 
mechanism in cells dubbed regulated 
intramembrane proteolysis or RIP 
(Brown et al., 2000).
The identification of presenilin 1 
(PS1, a.k.a. S182) and presenilin 2 (PS2) 
in humans was followed shortly by the 
realization that the Caenorhabditis ele-
gans homolog (Sel-12) played a neces-
sary role in Notch signaling, specifically 
in the release of the Notch intracellular 
domain (NICD) from its transmem-
brane precursor. Subsequent studies 
in worms, flies, and mammals estab-
lished presenilin as the active site of 
a four-protein complex (γ-secretase) 
that cleaves many type 1 membrane 
proteins within the lipid bilayer at two 
or more bonds (reviewed in Kopan and 
Ilagan, 2004) (see Figure 1). Missense 
mutations in PS1 or PS2 (more than 
160 are now known) cause a subtle but 
ultimately lethal shift in the cleavage of 
the transmembrane domain of amyloid 
precursor protein (APP). This results 
in an increase in the ratio of the 42- 
to 40-residue amyloid-β protein (Aβ), 
leading to Aβ aggregation and AD.Cell 131, OPresenilin and Its Partners
The findings that γ-secretase activ-
ity could be dramatically reduced 
by either presenilin deficiency or 
transition-state analogs for aspartyl 
proteases together suggested that 
presenilin might be a new aspartyl 
protease with a membrane-embed-
ded active site. Sequence align-
ments showed two aspartates that 
are predicted to reside in adjacent 
transmembrane domains and are 
completely conserved in metazoans. 
Mutation of either of these aspartates 
dramatically reduced γ-secretase 
activity, suggesting that they serve 
as the active site (Wolfe et al., 1999). 
Presenilins are cleaved into two 
stable pieces, an N-terminal frag-
ment (NTF) and a C-terminal frag-
ment (CTF), that remain associated 
as a heterodimer. This heterodimer 
is tightly regulated by limiting cellu-
lar factors and becomes associated 
with large complexes (Kopan and 
Ilagan, 2004). All of this suggested 
that γ-secretase is a multiprotein 
complex, with the PS heterodimer 
as its catalytic component and the 
cofactors titrating the levels of active 
protease in a cell. Consistent with 
this view, the interface between the 
NTF and CTF of PS1 is the molecu-
lar target of transition-state analog 
inhibitors of γ-secretase, suggest-
ing that the active site resides at this 
interface, with each presenilin sub-
unit contributing one of the catalytic 
aspartates.ctober 19, 2007 ©2007 Elsevier Inc. 215
Figure 1. γ-Secretase in Biology and 
Disease
(Top) The γ-secretase complex is comprised 
of the integral membrane proteins presenilin 
(as NTF and CTF subunits; orange and yellow, 
respectively), nicastrin (bright green), Aph-1 
(blue), and Pen-2 (red), with the active site in-
side presenilin at the NTF-CTF interface. Mem-
brane protein stubs serving as substrates (pale 
green) dock both on the outer surface of pre-
senilin at the NTF-CTF interface and with the 
nicastrin ectodomain before entering into the 
internal active site. 
(Middle left) Proteolysis by γ-secretase is in-
volved in certain cell-signaling events (and 
other functions such as adhesion). After ect-
odomain shedding, typically by a membrane-
tethered metalloprotease, the substrate is 
cleaved by γ-secretase to release an intra-
cellular domain that triggers transcriptional 
regulation. 
(Middle right) Proteolysis by γ-secretase is 
involved in membrane protein turnover. Re-
moval of protein stubs from the membrane by 
γ-secretase is followed by further degradation 
(e.g., by the proteasome). 
(Bottom left) Misregulation of Notch signal-
ing can lead to cancer. The Notch substrate 
is cleaved in at least two positions, at the S3 
position to release the intracellular domain 
(NICD) and at the S4 position to release a 
small peptide (Nβ). 
(Bottom right) The pathogenesis of Alzheimer’s 
disease involves production of Aβ peptides. 
Cleavage of APP substrate at the ε position 
releases the intracellular domain (AICD), while 
cleavage at the γ position releases aggrega-
tion-prone Aβ peptides.Identifying the limiting cofactors 
of γ-secretase and reconstituting the 
proteolytic complex in cells solidi-
fied presenilin’s role as the catalytic 
component. Coimmunoprecipitation 
experiments with presenilin led to the 
discovery of Nicastrin, a single pass 
membrane protein, as a required 
component of the complex. Mean-
while, genetic screens in C. elegans 
identified the multipass membrane 
proteins Aph-1 and Pen-2 also as 
essential components of the com-
plex (reviewed in De Strooper, 2003). 
Overexpression of all four compo-
nents (presenilin, Nicastrin, Aph-1, 
and Pen-2; see Figure 1) resulted in 
elevated γ-secretase activity. Coex-
pression in the budding yeast Sac-
charomyces cerevisiae is especially 
compelling: this organism does not 
possess γ-secretase activity, nor does 
it encode any of these four proteins. 
Purification of γ-secretase to virtual 
homogeneity (Fraering et al., 2004) 
revealed just these four proteins, indi-
cating that they are both necessary 
and sufficient for protease activity.216 Cell 131, October 19, 2007 ©2007 ElsNevertheless, recent work sug-
gests that other proteins may inter-
act with the complex and regulate its 
function. At least two proteins have 
been reported as potential modula-
tory subunits: CD147 and TMP21. 
The type I membrane glycoprotein 
CD147 copurified with γ-secretase 
from human cell lines; reduction of 
CD147 using RNA interference (RNAi) 
increased Aβ production, suggest-
ing that CD147 downregulates Aβ 
(Zhou et al., 2005). The cargo pro-
tein TMP21 was reported to differ-
entially regulate the Aβ-producing 
midtransmembrane γ cleavage with-
out affecting the ε cleavage closer 
to the membrane-cytosol interface, 
which releases the APP intracellular 
domain (AICD) into the cytosol (Chen 
et al., 2006) (see Figure 1). Knock-
down of TMP21 increased 40- and 
42-residue Aβ production without 
altering AICD levels. However, cleav-
age of APP substrate should neces-
sarily produce equimolar amounts 
of AICD and Aβ, as has been clearly 
established (Kakuda et al., 2006). evier Inc.In addition, the retrieval receptor 
Rer1p was recently reported to bind 
to immature Nicastrin and compete 
with Aph-1. In this way, Rer1p could 
regulate γ-secretase assembly in the 
endoplasmic reticulum (ER) and early 
Golgi (Spasic et al., 2007). In contrast, 
another report showed Rer1 interact-
ing with unassembled Pen2 (Kaether 
et al., 2007). These initial reports 
require confirmation, but the study of 
proteins that interact with and modu-
late γ-secretase is a fertile field for the 
future and may reveal new therapeu-
tic targets.
The biochemical roles of the vari-
ous components of the γ-secretase 
complex are only partially under-
stood. Presenilin contains a docking 
site (Kornilova et al., 2005) where the 
transmembrane domain of the sub-
strate interacts prior to its entry into 
the internal active site, which should 
contain water and the two catalytic 
aspartates. Nicastrin plays a role in 
substrate recognition: its ectodomain 
resembles an aminopeptidase but 
lacking key catalytic residues, and 
this domain can interact with the N 
terminus of γ-secretase substrates 
(Shah et al., 2005) (see Figure 1). The 
shedding of the substrate’s ectodo-
main (e.g., by either α- or β-secretase 
in the case of APP) thus allows the 
free N terminus of the membrane-
retained stub to interact with Nicas-
trin. Aph-1 is thought to function as 
a scaffold for the γ-secretase com-
plex, assembling first with Nicastrin 
and then with presenilin and Pen-2. 
Pen-2 serves as a trigger for endo-
proteolysis of the presenilin holo-
protein into the active heterodimer, 
although it is independently required 
for γ-secretase activity as well. There 
are at least three variants of Aph-1 in 
mammalian cells, but cellular expres-
sion of either PS1 or PS2 with each 
of these variants (plus Nicastrin and 
Pen-2) yielded six different com-
plexes that produced similar cleav-
age patterns with APP (Shirotani et 
al., 2007). Studies with knockout mice 
have established some differential 
effects of the two presenilin variants 
and also of the Aph-1 isoforms (for 
example, see Serneels et al., 2005), 
perhaps due to varying tissue expres-
sion. Moreover, these complexes may 
be differentially localized within cells, 
where they could have distinct prote-
olytic functions. Such questions now 
need to be resolved.
Toward Elucidation of Structure
Defining the structure of the protease 
complex is another major focus of 
ongoing work. Cysteine mutagenesis 
coupled with crosslinking to chemical 
probes suggests the existence of a 
hydrophilic pore leading from the lumi-
nal/extracellular milieu to the catalytic 
aspartates; this method has also sug-
gested specific sites for binding of 
inhibitors (Sato et al., 2006a; Tolia et 
al., 2006). The size and stoichiometry 
of the γ-secretase complex, critical to 
the elucidation of its structure, has 
been a matter of controversy, with 
estimates ranging from ?150 KDa to 
?2 MDa. Although some studies sug-
gested that the complex contains two 
PS molecules at its catalytic core (for 
example, see Schroeter et al., 2003) 
and that the putative PS homolog, 
signal peptide peptidase (SPP), like-wise can form a dimer, more recent 
findings reveal that only one PS mol-
ecule per complex is sufficient for 
γ-secretase activity (Sato et al., 2007) 
and that monomeric SPP is proteolyt-
ically active (Narayanan et al., 2007).
Purification of γ-secretase has 
allowed single particle analysis by 
electron microscopy (EM) to pro-
vide the first images of the protease 
(Lazarov et al., 2006). Although the 
resolution was low (?15 Å), certain 
structural features could be gleaned, 
including an interior chamber remi-
niscent of the proteasome and two 
openings facing the luminal and cyto-
plasmic sides that could provide entry 
of water molecules and exit ports for 
the two proteolytic products. A sec-
ond EM structural study reported 
images at ?55 Å resolution (Ogura et 
al., 2006), making structural interpre-
tation difficult. Ongoing studies using 
cryo-EM and/or 2D crystallization 
may provide higher resolution, yield-
ing better clues to the catalytic mech-
anism, substrate interactions, and 
inhibitor binding. Three-dimensional 
crystallization of the entire complex, 
with its minimum of 19 transmem-
brane domains, will present a particu-
lar challenge and should be preceded 
by the crystallization of PS homologs 
like SPP that can act alone.
Many Presenilin Substrates
While APP was the first substrate 
of γ-secretase to be recognized, it 
is now apparent that this protease 
evolved to cleave Notch and sev-
eral other functionally critical type 
1 membrane glycoproteins (Kopan 
and Ilagan, 2004). Although the num-
ber of reported substrates already 
exceeds three dozen, unbiased pro-
teomic searches may uncover many 
more. There is extensive evidence 
that PS/γ-secretase cannot efficiently 
cleave full-length type 1 proteins; 
most of the ectodomain must first be 
removed (generally by metallopro-
teases such as ADAM-10 or -17) to 
enable intramembrane cleavage of 
the remaining stub. Shedding of the 
large ectodomain may remove steric 
hindrance to the γ cleavage and may 
also allow subtle relaxation of the 
transmembrane α helix to enable Cell 131, Ocaccess of the catalytic aspartates to 
the amide bonds fated for cleavage. 
Whether most or all type 1 membrane 
proteins that undergo ectodomain 
shedding become γ-secretase sub-
strates remains to be seen.
The known substrates have many 
diverse functions, including cell fate 
determination (Notch and Jagged), 
cell-cell adhesion (N- and E-cad-
herins, CD44, and Nectin-1α), regula-
tion of ion conductance (β2 subunit 
of the voltage-gated sodium chan-
nel), growth factor-dependent recep-
tor tyrosine kinase signaling (ErbB4), 
and neurotrophin signaling (p75 
NTR). Although the early implication 
of Notch as a vital substrate raised 
the possibility that most or all sub-
strates underwent γ-secretase cleav-
age to release signaling fragments to 
the nucleus, this may not be a unify-
ing characteristic of the substrates. 
For example, γ-secretase cleavage 
of E-cadherin releases its bound 
protein partners, α- and β-catenin, 
from the actin cytoskeleton, thus 
contributing to adherens junction dis-
assembly; but the E-cadherin intrac-
ellular domain (ICD) is not known to 
be a nuclear signaling molecule. In 
the case of APP, several laborato-
ries have reported that the APP ICD 
can regulate gene transcription, with 
each laboratory identifying a different 
nuclear target. But none of these find-
ings was replicated when presenilins 
were genetically or pharmacologically 
inactivated or APP and its homologs 
were deleted in cells or mice (Hebert 
et al., 2006). At this juncture, nuclear 
signaling roles for the ICDs of APP 
and several other γ-secretase sub-
strates are not established, and RIP 
appears capable of conferring other 
functions.
Such considerations suggest that 
the PS/γ-secretase complex evolved 
principally as an efficient mechanism 
to clear out the membrane-embedded 
domains of many different type 1 pro-
teins, a function that has earned this 
complex the name proteasome of the 
membrane (Kopan and Ilagan, 2004; 
Small, 2002). If so, some of the many 
released ICDs may have been stable 
enough in the cytoplasm to acquire 
various physiological functions (e.g., tober 19, 2007 ©2007 Elsevier Inc. 217
nuclear signaling), whereas others were 
extremely labile and essentially without 
activity (see Figure 1). SPP could per-
form the same general function for cer-
tain type 2 membrane proteins. A ques-
tion for future research is whether new 
types of I-CLiPs will be discovered that 
turn over the transmembrane domains 
of polytopic proteins.
Nonproteolytic Functions of 
Presenilin
A few studies have suggested that PS 
can also mediate functions that are 
independent of its proteolytic activ-
ity. Not all attempts to show this phe-
nomenon have incorporated a “prote-
olytically dead” PS molecule having 
its active site asparates mutated (e.g., 
PS1 D257A). One that has is the report 
that mouse embryonic fibroblasts 
cultured from PS1/2 double knock-
out mice have increased calcium ion 
concentrations in the ER and that this 
phenotype can be rescued equally 
by transfecting wild-type or D257A 
PS1 constructs (Tu et al., 2006). The 
authors propose that the PS holopro-
tein forms ER calcium ion leak chan-
nels and that the D257A mutant, which 
does not undergo endoproteolysis, 
can function in this way. Other reports 
have suggested that PS1 participates 
in the regulation of intracellular protein 
trafficking independently of its pro-
teolytic activity (most recently, Wang 
et al., 2006), although proteolytically 
inactive mutants could cause satura-
tion of internalization pathways due to 
massive accumulation of uncleaved 
γ-secretase substrates. Some stud-
ies claiming a trafficking or other 
nonproteolytic function of PS did not 
examine D257A PS constructs. More-
over, the mechanisms of the observed 
changes are unclear, and one cannot 
yet exclude indirect effects secondary 
to PS-mediated substrate cleavage. 
Additional studies are now needed to 
unequivocally confirm nonproteolytic 
PS functions.
Evolutionary Implications
Presenilin and the γ-secretase com-
plex are highly conserved in metazo-
ans, in which the protease is essential 
for differentiation and development 
due to its role in Notch signaling. 218 Cell 131, October 19, 2007 ©2007 EGenetic alterations in γ-secretase 
components that reduce or eliminate 
proteolytic function lead to develop-
mental abnormalities similar to those 
seen with Notch deficiency. Thus, 
coevolution of the PS complex mem-
bers and the Notch pathway was 
likely to be a key phase that made the 
emergence of multicellular animals 
possible. Presenilin’s acquisition of 
partner proteins that are essential 
for proteolytic activity suggests that 
the enzyme requires tight regulation. 
The development of such regulation 
likely coincided with the emergence 
of the Notch pathway as a powerful 
mechanism for controlling cell differ-
entiation.
Distant presenilin homologs have 
been discovered, and one of these, 
SPP, apparently functions as a pro-
tease on its own without the need 
for protein partners (Weihofen et al., 
2003). SPP and SPP-like proteases 
are found in unicellular organisms 
as well, suggesting that intramem-
brane aspartyl protease catalysis 
is ancient. As its name implies, the 
major role of SPP is to clear out rem-
nant signal peptides left behind in the 
ER membrane after their release by 
signal peptidase, suggesting that the 
biological function of ur-presenilins 
was to help remove proteins from the 
membrane. Over time, the preseni-
lin-generated cleavage products of 
certain proteins may have evolved 
new functions, such as cell signal-
ing. γ-Secretase retains this general 
clearing function in addition to its 
putatively more recently acquired 
functions such as Notch and Erb-B4 
signaling. Likewise, certain products 
generated by SPP have acquired bio-
logical functions, such as in immune 
surveillance in mammals.
One of the SPP-like proteases, 
SPPL2b, was recently found to 
cleave tumor necrosis factor α in cells 
(Fluhrer et al., 2006), and the released 
intracellular domain can stimulate 
IL-12 production in activated dendritic 
cells (Friedmann et al., 2006). Exami-
nation of the products generated by 
SPPL2b revealed a double cleavage 
of the substrate, similar to that by 
γ-secretase. Another polytopic mem-
brane aspartyl protease family, the lsevier Inc.type IV prepilin proteases (TFPPs), 
possesses PS-like sequence motifs 
that contain the catalytic aspartates 
(Steiner et al., 2000); however, the 
aspartate dyad of TFPP apparently 
lies outside the membrane, and these 
proteases do not seem evolutionarily 
related to PS and SPP.
PS/γ-secretase and the SPP fam-
ily exhibit key differences. First, PS 
requires three different membrane 
protein cofactors for proteolytic func-
tion, whereas the SPPs can carry out 
proteolysis on their own (Narayanan et 
al., 2007; Weihofen et al., 2003). Sec-
ond, PS and SPP are oriented oppo-
sitely in the membrane (Friedmann et 
al., 2004; Laudon et al., 2005; Nyborg 
et al., 2004). This flipped topology is 
consistent with the third difference, 
that PS/γ-secretase cuts type I inte-
gral membrane proteins (oriented N 
to C terminus from the lumenal/extra-
cellular space to the cytosol), whereas 
the SPPs cleave type II integral mem-
brane proteins (oriented C to N termi-
nus) (Weihofen et al., 2003). Notwith-
standing these important differences, 
PS/γ-secretase and SPP display bio-
chemical and pharmacological simi-
larities. Upon solubilization from the 
asymmetric environment of the lipid 
bilayer, the two proteases can cleave 
the same substrates (Sato et al., 
2006b). This finding suggests that the 
two proteases, with their conserved 
aspartate motifs, have similar active 
sites, a concept supported by the fact 
that certain transition-state analogs 
can inhibit both proteolytic activities 
(Weihofen et al., 2003). Other small 
organic molecules, including helical 
peptide-type docking site inhibitors, 
block the activities of both proteases, 
implying common binding sites for 
these agents as well (Sato et al., 
2006b; Weihofen et al., 2003).
The intramembrane aspartyl pro-
tease family could have served a role 
in membrane protein extrusion prior 
to acquiring transmembrane residues 
that allow proteolysis. Such a function 
would require a means of lateral entry 
of transmembrane domains prior to 
extrusion. Indeed, SPP is critical for 
dislocating the class I major histo-
compatibility complex (MHC) from 
the membrane during infection by 
human cytomegalovirus (Loureiro et 
al., 2006), allowing the virus to evade 
detection by the immune system. 
Whether the proteolytic function of 
SPP is required for MHC dislocation is 
unknown, although MHC is extruded 
as a full-length protein (i.e., without 
intramembrane proteolysis). Another 
possibility is that the intramembrane 
aspartyl proteases were originally 
channel proteins, an idea supported 
by the aforementioned finding that PS 
holoprotein can apparently serve as 
an ER calcium leak channel indepen-
dent of its role in γ-secretase (Tu et al., 
2006). Presenilin’s ability to serve as 
a calcium channel may be vestigial, a 
biochemical relic of an ancient func-
tion acquired prior to the acquisition 
of the intramembrane aspartates.
PS/γ-Secretase in AD Pathogen-
esis and Treatment
The identification of presenilin as the 
catalytic component of γ-secretase 
provides a linchpin for the amyloid 
(Aβ) hypothesis of AD: all of the 
mutations currently known to cause 
autosomal dominant AD occur either 
in the substrate (APP) or the pro-
tease (presenilin) of the reaction that 
produces Aß. Nevertheless, it has 
been suggested that the clinical PS1 
and PS2 mutations confer the dis-
ease phenotype principally through 
mechanisms other than promoting 
Aβ42 accumulation. This idea is often 
coupled with a discussion of whether 
the AD-causing mutations represent 
a gain or loss of presenilin function. 
One line of reasoning begins with 
the observation that conditional PS 
knockout mice develop neurode-
generation and deficits in cognition 
reminiscent of key features of AD 
(Shen and Kelleher, 2007). Thus, it 
is argued, presenilin loss of func-
tion confers an AD-like state. But 
there are three key misunderstand-
ings here. First, many genetic altera-
tions in mice can produce neuronal 
loss and impaired cognition, and 
these nonspecific phenotypes also 
occur in various human disorders of 
diverse etiology. Second, any mouse 
phenotype that lacks Aβ accumula-
tion (as PS knockouts do) cannot 
be thought of as a model for AD, as the human disease is defined by the 
invariant accumulation of Aβ. Third, 
if PS mutations in familial AD con-
ferred a clinically important loss of 
neural function independent of their 
elevation of Aβ42/40 ratios, then the 
detailed clinical and neuropathologi-
cal phenotypes of the carriers would 
be expected to be different in part 
from those with APP mutations, but 
the phenotypes are generally indis-
tinguishable (i.e., typical AD).
As to whether clinical PS muta-
tions confer gain or loss of function, 
this simple dichotomy has been used 
to describe the effects of mutations 
in newly discovered genes during 
development, often in invertebrates. 
But once the specific biochemi-
cal activity of a gene product is 
well understood, mutations may be 
found to confer neither loss nor gain 
of function exclusively but some of 
both. Many PS mutations cause less 
γ-secretase cleavage of APP at the 
Aβ40-41 peptide bond relative to 
cleavage at the Aβ42-43 bond, thus 
conferring both “loss” and “gain” of 
proteolytic activity, depending on the 
bond in question. Even if one views 
the clinical PS mutations as confer-
ring an overall loss of proteolytic 
function, the outcome for the organ-
ism is the gain of a toxic product, i.e, 
more synaptotoxic Aβ. 
Recently, a reconciliation of the 
seemingly antithetic views of “loss” 
and “gain” of function has been pro-
posed (De Strooper, 2007; Wolfe, 
2007). Key to this unifying idea is 
the finding that γ-secretase appar-
ently cuts at the ε site first, to pro-
duce either a 48- or 49-residue Aβ 
(Kakuda et al., 2006; Wolfe, 2007). 
Subsequent cuts every 3–4 resi-
dues (i.e., every helical turn of the 
substrate) ultimately produce the 
39–43 residue Aβ peptides that are 
secreted from the cell. Familial AD 
mutations in PS typically reduce the 
catalytic efficiency of γ-secretase, 
having the net result that while 
less Aβ may be produced, a larger 
proportion will be longer Aβ pep-
tides such as Aβ42. Thus, a loss of 
function (reduced proteolytic activ-
ity) could lead to a gain of function 
(increased Aβ42/40 ratio).Cell 131, OIn short, focusing on gain or loss 
of function is too simple to be useful 
once one knows the specific biochem-
ical activity (in this case, endoprote-
olysis) that a gene product confers. 
Instead, we need to decipher at the 
atomic level exactly how a PS mis-
sense mutation alters the conforma-
tion of the active site to shift its cleav-
age specificity. And arguing that the 
clinical PS mutations may cause AD 
by perturbing the processing of other 
PS substrates (e.g., Notch) ignores 
the key observation that mutations 
in just a single PS substrate (APP), 
but in no others, produce AD hav-
ing a clinicopathological phenotype 
indistinguishable from that of the PS 
mutations themselves. Parsimony 
supports a common effect of both PS 
and APP mutations: to increase brain 
Aβ42 levels and thus enhance the for-
mation of synapse-impairing oligom-
ers. It is also important to recall that 
in the overwhelming majority of AD 
patients, PS is wild-type, and factors 
unrelated to alteration of Aβ42 pro-
duction by γ-secretase are at fault.
As to its attractiveness as a ther-
apeutic target, presenilin is often 
viewed adversely because of its vital 
function in cleaving Notch and other 
important substrates. But there is 
now good evidence that small mol-
ecules can be found that have large 
therapeutic indices—i.e., they bind to 
the γ complex in a way that inhibits 
the cleavage of Notch far less than 
that of APP. Such “modulators” of 
γ-secretase include certain nonsteroi-
dal antiinflammatory drugs (NSAIDs) 
that apparently shift cleavage speci-
ficity from Aβ42 by one turn down 
the transmembrane helix to Aβ38 
(Weggen et al., 2001). These com-
pounds are therapeutically attractive, 
assuming they otherwise have salu-
tary pharmacological properties. One 
“smart γ-secretase inhibitor” of this 
type, R-flurbiprofen (which no longer 
inhibits cyclooxygenase), is already in 
late-stage human trials.
Other γ-secretase modulators 
include compounds identified from 
kinase inhibitor collections. These 
compounds do not shift where 
γ-secretase cuts APP; rather, they 
block Aβ production altogether ctober 19, 2007 ©2007 Elsevier Inc. 219
without inhibiting Notch proteoly-
sis. The discovery of such agents 
emerged from the finding that ATP 
and other nucleotides can stimulate 
Aβ production (Netzer et al., 2003), 
even in purified γ-secretase prepa-
rations (Fraering et al., 2005), sug-
gesting a nucleotide binding site 
on the enzyme complex and/or the 
APP substrate that serves to allos-
terically regulate substrate selectiv-
ity. As with the NSAIDs, however, 
more work is needed to improve the 
potency of these modulators and to 
better establish their biochemical 
mechanism of action.
γ-Secretase As a Target for Cancer
That PS/γ-secretase is required for 
Notch signaling is considered an 
obstacle in developing inhibitors as AD 
therapeutics. However, this potential 
problem should be an advantage for 
chemotherapy of certain cancers. The 
critical function of Notch in differentia-
tion, in particular to maintain precursor 
cell niches, can go awry, with excess 
stimulation of Notch signaling caus-
ing overproliferation of these immature 
precursors. The developmental path-
ways Hedgehog and Wnt are consid-
ered important targets for cancer che-
motherapy for similar reasons.
Excessive Notch signaling has been 
implicated in several types of neoplas-
tic diseases (Shih Ie and Wang, 2007). A 
chromosomal translocation that results 
in a truncated, constitutively active form 
of Notch1 is found in 10% of human 
T cell acute lymphoblastic leukemia 
(T-ALL) cases, and activating point 
mutations in Notch1 have been found 
recently in ?50% of all T-ALL. Eleva-
tion of Notch3 expression is implicated 
in subsets of nonsmall cell lung cancer 
and ovarian cancer, and activation of 
Notch signaling is also implicated in 
breast cancer. γ-secretase inhibitors 
can block proliferation of Notch-de-
pendent tumor cell lines and reduce 
tumor growth in mouse models, and 
one inhibitor has entered phase I clini-
cal trials for T-ALL and breast cancer. 
Notch signaling also plays an important 
role in angiogenesis and may be critical 
for self-renewal of cancer stem cells; 
inhibiting these Notch functions is con-
sidered a worthy anticancer strategy.220 Cell 131, October 19, 2007 ©2007 EIn spite of this promise, the same 
caveats about the use of γ-secretase 
inhibitors in AD apply here. Blocking 
Notch signaling too much and for too 
long may lead to unacceptable toxic 
effects, such as gastrointestinal dys-
function and immunosuppression. 
The hope is that a therapeutic win-
dow exists, especially if certain types 
of cancer cells are overly dependent 
on Notch signaling for survival. A fur-
ther hope is that γ-secretase inhibi-
tors could be given for shorter peri-
ods of time and in smaller doses, in 
combination with other antineoplas-
tic agents. Such regimens may avoid 
complications of chronically block-
ing γ-secretase processing of sub-
strates.
The Future: Questions Abound
Despite a growing understanding of 
presenilin biology, there are at least 
six key questions that remain to 
be answered. How does presenilin 
select among so many competitive 
substrates? How are protein sub-
strates translocated into its active 
site? Precisely how does PS carry out 
hydrolysis of peptide bonds within 
a hydrophobic environment? Does 
the lipid composition of membranes 
strongly regulate substrate selection 
and cleavage specificity? Does pre-
senilin function differently in different 
cell types and at distinct subcellular 
loci? And how do pharmacological 
modulators subtly alter Aβ produc-
tion? There is reason to be cautiously 
optimistic that pharmacological 
modulation of PS/γ-secretase activ-
ity will become a viable therapeutic 
approach for AD and possibly for 
cancers as well. Given the remarkably 
wide range of substrates and biologi-
cal roles of γ-secretase discovered 
so far, other therapeutic applications 
may ultimately be revealed.
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